Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira Pharm Inc (NQ: PCRX )

16.57 -0.03 (-0.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pacira Pharm Inc

< Previous 1 2 3 Next >
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience 
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Second Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
From Pacira BioSciences
Via GlobeNewswire
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
Exposures Death
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
From Pacira BioSciences
Via GlobeNewswire
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Third Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback